Company news
Matricelf Ltd. (TASE:MTLF) news
Matricelf Ltd. news releases on 6ix. Latest, Sep 3, 2026: Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial…
Press releases & updates
Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program
September 3, 2026
Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones
July 9, 2026
Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury
June 22, 2026
Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion
June 17, 2026
Matricelf Enters Strategic Collaboration with Japan's CiRA Foundation to Advance Next-Generation Regenerative Manufacturing
March 30, 2026
Matricelf (TASE: MTLF) Enters Strategic Collaboration with Sheba Medical Center to Advance First in Human Clinical Program in Spinal Cord Injury
March 24, 2026
Matricelf Ltd. (TASE: MTLF) Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile of Its Personalized Spinal Cord Implant
March 4, 2026
Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy
March 3, 2026
Matricelf Named Most Innovative Company of 2026 at Advanced Therapies Week in San Diego
March 2, 2026
Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board
February 27, 2026
Matricelf to Attend The Digital Spine & Pain Neuroscience Summit 2026 in Phoenix, Arizona
February 26, 2026
Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments
March 11, 2025